HLA-A11.1/B2M(2)
Nomenclature
C57BL/6JSmo-B2mtm1(hB2M-linker-HLA-A*1101/H2-D1)Smoc
Cat. NO.
NM-HU-241354
Strain State
Repository Live
Gene Summary
Gene Symbol
B2M
Model Description
Validation Data

Fig.1 Expression analysis of hB2M and HLA-ABC on CD45+ cells in blood of HLA-A11.1/B2M humanized mice.
Leukocytes were collected from wild-type C57BL/6 mice(11 weeks old) and homozygous HLA-A11.1/B2M humanized mice(15.7 weeks old) , and analyzed by flow cytometry with anti-mB2M, anti-hB2M, anti-mH2D and anti-HLA-ABC. hB2M and HLA-ABC were exclusively detectable in HLA-A11.1/B2M humanized mice, whereas mB2M and mH2D were exclusively detectable in wild-type C57BL/6 mice.

Fig.2 Analysis of immune cell subpopulations in the blood (n=3 per group).
Leukocytes were collected from the blood of wild-type C57BL/6 mice (female, 8 weeks old; male, 9 weeks) and homozygous HLA-A11.1/B2M humanized mice (9 weeks old), and Flow cytometry analysis was performed to assess leukocyte subpopulations.
Abbr. WT, wild type; HO, homozygous.

Fig.3 Analysis of immune cell subpopulations in the spleen (n=3 per group).
Leukocytes were collected from the spleens of wild-type C57BL/6 mice (female, 8 weeks old; male, 9 weeks) and homozygous HLA-A11.1/B2M humanized mice (9 weeks old), and flow cytometry analysis was performed to assess leukocyte subpopulations.
Abbr. WT, wild type; HO, homozygous.
Fig.4 Detection of KrasG12V vaccine and peptide induced immune responses in HLA-A11.1/B2M mice by ELISpot assay.
Splenocytes from mice immunized with PBS, or KRAS G12V LNP-mRNA were collected and stimulated in vitro with RPMI 1640 medium(Non-stimulation), NY-ESO-1: 157–165, KRAS G12V: 8–16, or cell stimulation cocktail (PC), respectively. Upon stimulation with KrasG12V: 8-16 peptide, WT mice showed no response, whereas HLA-A11.1/B2M mice after KRAS G12V mRNA-LNP immunization generated a robust cellular immune response.

Fig.5 KrasG12V: 8-16 peptide tetramer+ T cells assays.
Splenocytes from mice immunized with PBS or KRAS G12V LNP-mRNA were collected and stimulated with the hHLA-11.1-restricted KRAS G12V: 8–16 peptide. Flow cytometry analysis revealed that the KRAS G12V mRNA-LNP vaccine predominantly elicited a strong antigen-specific CD8+ T cell expansion (~20%).

Fig.6 T-cell intracellular cytokine staining (ICS) assays.
Splenocytes from groups G1–G5 were collected and stimulated with PBS (NC), NY-ESO-1: 157–165, KRAS G12V: 8–16, or cell stimulation cocktail (PC), respectively and analyzed. Flow cytometry analysis revealed that only the hHLA-11.1/B2M mice immunized with KRAS G12V LNP-mRNA (G4) generated a large number of IFN-γ-positive CD4+ and CD8+ T cells.
You may also like
Workshop:Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more